Guggenheim Securities Downgrades Seattle Genetics to Neutral

Guggenheim Securities analyst Michael Schmidt downgrades Seattle Genetics (NASDAQ:SGEN) from Buy to Neutral.

Benzinga · 01/02/2020 13:02

Guggenheim Securities analyst Michael Schmidt downgrades Seattle Genetics (NASDAQ:SGEN) from Buy to Neutral.